Incorporating patient experiences in bladder cancer treatment: enhancing outcomes and QoL

0 Views

07/08/23

Benjamin Garmezy, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the incorporation of patients' experiences into the decision-making process to improve treatment outcomes and patient satisfaction in bladder cancer. The focus goes beyond shrinking tumors; it aims to ensure that patients can not only live longer but also live well. The Phase III JAVELIN Bladder 100 (NCT02603432) trial revealed that patients receiving chemotherapy followed by immunotherapy maintenance experienced low rates of severe adverse events, enabling them to continue treatment with minimal toxicity. This data highlights the importance of maintaining treatment efficacy while prioritizing patients' quality of life. Additionally, Dr Garmezy emphasizes the impact of surgical decisions on patients with VHL syndrome, recognizing that treatment choices should be made through open discussions, considering the patients' personal circumstances, daily activities, and job requirements. By tailoring treatment options to individual needs, healthcare professionals can guide patients towards decisions that are best suited for them. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.